Compare Cytokinetics Inc (CYTK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while Direxion Daily TSLA Bull 2X Shares trades at $12.5. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| CYTK | TSLL | |
|---|---|---|
Market Cap | $11.12B | — |
Sector | Technology | Leveraged / Inverse |
52-Week High | $87.26 | $23.03 |
52-Week Low | $33.23 | $10.29 |
Enterprise Value | $11.59B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
TSLL is trading at $12.27, down 6.26% today amid bearish technical signals. The stock faces selling pressure with all 13 moving averages indicating bearish momentum while oscillators remain neutral. Recent news highlights derivative-based ETF strategies and Tesla earnings implications. The company has a future dividend scheduled for June 2026.
The technical outlook appears challenging with strong bearish momentum, though the stock is trading near key support at $12. Fundamental analysis is limited due to unavailable financial ratios. Investors face volatility risks from the leveraged ETF structure and dependency on underlying Tesla performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
